Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers

• Prif Awduron: Hengbang Wang (Awdur), Yun Yang (Awdur), Zi Chen (Awdur), Lei Fu (Awdur), Min Yu (Awdur), Lixin Jiang (Awdur), Cunlin Wang (Awdur), Lichuang Men (Awdur), Ilisse Minto (Awdur), Dajun Yang (Awdur), Yifan Zhai (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2024-09-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Olverembatinib (HQP1351) is a BCR‐ABL1 tyrosine kinase inhibitor with promising clinical activity. It is approved in China for the treatment of patients with chronic myeloid leukemia harboring drug‐resistant mutations, such as T315I. In vitro studies suggested that metabolism of olverembati...